Everything Narracomm has filed on California AI Startups.
| Headline | Date | Coverage |
|---|---|---|
| Aurora Innovation – Self-Driving Hardware And Software | 25 Jun 2026 | Read More → |
| Arcwise – Data-Driven Decision Platform | 25 Jun 2026 | Read More → |
| Airtop – AI Agent Platform For Sales And Marketing | 25 Jun 2026 | Read More → |
| Astor – AI Investment Advisor | 24 Jun 2026 | Read More → |
| Serafis – Narrative Intelligence | 24 Jun 2026 | Read More → |
| Zarna – AI Associates | 24 Jun 2026 | Read More → |
| Levocred – AI OS For Structured Credit | 24 Jun 2026 | Read More → |
| S2.dev – Serverless API | 24 Jun 2026 | Read More → |
| Cusman AI | 24 Jun 2026 | Read More → |
| Merge Labs (Merge.io) -Brain-Computer Interfaces | 24 Jun 2026 | Read More → |
| humans& – AI Models and Systems Lab | 23 Jun 2026 | Read More → |
| Patientdesk.ai – An AI-Powered Voice Agent For Dentists | 23 Jun 2026 | Read More → |
| Archal.AI – Eval For Autonomous Software | 22 Jun 2026 | Read More → |
| FinalDose — Programmable DNA-Targeted Cancer Therapy Platform | 22 Jun 2026 | Read More → |
humans& (humansand.ai) is a human-centric frontier AI lab developing models and systems that enhance collaboration, communication, and decision-making by acting as connective tissue for organizations and communities. Founded in September 2025, it emphasizes AI augmentation of human relationships and coordination…
Patientdesk.ai provides an AI-powered voice agent and front/back-office automation system for dental practices that handles inbound calls 24/7, performs real-time insurance verification during calls, books appointments directly into existing practice management systems, follows up on leads, and processes claims Founded…
Archal.ai is the evaluation platform for autonomous software. It lets developers and teams test AI agents and autonomous code against realistic, stateful clones of third-party SaaS services (GitHub, Slack, Stripe, and similar) without hitting live production systems. Founded in 2026,…
FinalDose is developing a programmable drug platform that uses DNA sequence recognition to identify and destroy cancer cells while leaving healthy cells untouched, starting with a modality aimed at all cancers. Founded in 2025 and based in San Francisco, the…